Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma : Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide
✍ Scribed by Peter J. Hoskin; Michelle I. Saunders; Stanley Dische
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 88 KB
- Volume
- 86
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
✦ Synopsis
BACKGROUND.
In animal models carbogen (normobaric 95% oxygen, 5% carbon dioxide) provides significant enhancement of local tumor control with fractionated radiotherapy. This approach to radiosensitization has been evaluated in the treatment of patients with bladder carcinoma using radical radiotherapy.
METHODS.
Sixty-one patients with locally advanced bladder carcinoma were treated using a Phase II trial delivering radiotherapy to the bladder (50 -55 Grays in 20 daily fractions over 4 weeks) with inhalation of carbogen alone in 30 patients and the addition of oral nicotinamide (80 mg/kg) prior to radiotherapy with carbogen in 31 patients. The results from these 61 patients were compared with those from two earlier attempts at hypoxic sensitization: the second Medical Research Council (MRC) hyperbaric oxygen trial in patients with bladder carcinoma and a Phase III trial of misonidazole with radiotherapy in patients with bladder carcinoma performed at Mount Vernon Hospital.